Country for PR: United Kingdom
Contributor: PR Newswire Europe
Wednesday, June 10 2020 - 18:56
Galderma Global Research Reveals Struggles of People With Rosacea and Psoriasis of the Face Experiencing a Lack of Control and Impact on Mental Wellbeing
LAUSANNE, Switzerland, June 10, 2020, /PRNewswire-AsiaNet/--

A new expert-authored Galderma report 
[ ] released today reveals the 
true extent of the hidden burden of rosacea and psoriasis of the face on 
patients' lives. 

Findings of this global survey – Beyond the visible: rosacea and psoriasis of 
the face – show that regardless of the disease (rosacea (ROS) or psoriasis of 
the face (PsO)), almost all (90%) of the patients surveyed felt their disease 
was partially or totally uncontrolled, and experienced a similar impact on 
working life, with 40% of sufferers across both diseases admitting that their 
condition impairs their work activities.1
Over half of patients surveyed felt their disease significantly affected their 
daily lives (58% ROS vs 55% PsO), with 1 in 2 people self-reporting 
moderate-to-severe depression† (49% ROS vs 54% PsO) and at least a third 
self-reporting moderate-to-severe anxiety‡ (34% ROS vs 43% PsO).[1]

However, when it comes to assessing new patients, quality of life (QoL) and 
psychosocial impact is not top of mind for HCPs, with only a limited number of 
doctors surveyed mentioning that they investigate QoL issues in practice (9% 
ROS vs 22% PsO).1 
Based on these findings involving over 600 patients with facial skin disease 
(rosacea or psoriasis)* and 361 doctors across 6 countries, the report explores 
the challenge of controlling the two diseases, quality of life issues, 
similarities and disparities in disease management, mental health impacts, as 
well as HCP attitudes and approaches, with the aim of improving disease 

Commenting on the findings, Prof. Dr Jerry Tan, Adjunct Professor, Western 
University, Ontario, Canada, and one of the expert authors of the report says: 

"This ground-breaking study is helping to evolve treatment practice in rosacea 
and psoriasis. There is much to be learned from current practice and the 
striking similarities between rosacea and psoriasis of the face, in terms of 
impact on patients' productivity and daily lives, which further demonstrates 
the importance of improving outcomes." 

Invisible symptoms such as stinging, burning and itching are driving disease 
burden for many sufferers, yet only a quarter of doctors surveyed are routinely 
assessing these symptoms with their rosacea patients (27% ROS vs 40% PsO).[1] 

Though more than half of all patients in the survey, regardless of disease, 
were ashamed of their condition, it was rosacea patients that were more likely 
to blame themselves for flare-ups (28% ROS vs 20% PsO), said they experience 
low self-esteem (34% ROS vs 20% PsO) and low confidence (30% ROS vs 18% PsO).[1]

Almost half (46%) of rosacea patients and almost a third (30%) of patients with 
psoriasis on the face still believed their disease was triggered by lifestyle 
choices, demonstrating a need for increased patient education.[1]

The benefits of achieving 'clear' (IGA 0) are well-established in both 
diseases, and positively, 44% of rosacea patients surveyed recognized that 
'clear' skin is possible (vs 35% PsO).[1]
Encouragingly, the majority of sufferers surveyed expressed a desire to 
understand more about their disease (73% ROS vs 65% PsO), leading the report's 
authors to highlight the need for HCPs to empower their patients through 
knowledge, discuss the invisible as well as visible impacts, and help them to 
understand the benefits of aiming for 'clear' (IGA 0) to improve outcomes.[1]

* All patients surveyed claimed to be experiencing a moderate to severe disease 
impact on their lives
† Self-reported, measured using Patient Health Questionnaire-9 (PHQ-9) 
‡ Self-reported, measured using General Anxiety Disorder-7 scale (GAD-7)


1.  Steinhoff M, et al. Beyond the visible: rosacea and psoriasis of the face. 
The BMJ Hosted Content 2020. Available from: Date accessed: June 2020. 
2.  Gether L, et al. Incidence and prevalence of rosacea: a systematic review 
and meta-analysis. Br J Dermatol. 2018;179(2):282-289. 
3.  International Federation of Psoriasis Associations. World Psoriasis Day. 
Available at: Date 
accessed: June 2020. 
4.  Parisi R, et al. Global epidemiology of psoriasis: a systematic review of 
incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385.  

About rosacea

Rosacea is a common inflammatory skin disease that presents variable clinical 
characteristics, of which the most common are flushing, persistent erythema, 
and inflammatory lesions. It mainly affects the central areas of the face, such 
as the cheeks and nose. The disease can affect both adult men and women, 
usually after the age of 30. Additionally, symptoms such as stinging, burning 
and increased sensitivity of the skin are common. The eyes are often affected, 
and might present as red, dry or itchy.

Although the cause of the disease is still under debate, various trigger 
factors are known, including spicy foods, alcohol, emotional stress, 
sun/UV-exposure, hot baths and beverages. Demodex, generally harmless mites, 
can also be found in the skin in an elevated quantity in people with rosacea.

Rosacea may worsen over time if left untreated. People that suspect they suffer 
from rosacea should visit their dermatologist or healthcare provider for 
diagnosis and discuss what treatment is right for them. Because rosacea is a 
highly visible disease, it is known to cause embarrassment and anxiety in some 
patients, which in turn may cause frustration and have a negative impact on 
their social life.

About psoriasis

Psoriasis is a chronic, inflammatory skin disease estimated to affect 
approximately 125 million people worldwide.3 It ranges in severity from a few 
scattered red, scaly plaques (lesions), to involvement of almost the entire 
body surface. It may worsen with age, or wax and wane in its severity.[4]

Having psoriasis can be a heavy physical, social, emotional and economic 
burden. It may also increase the risk of developing other conditions like heart 
disease or diabetes. While there is currently no cure for psoriasis, there is a 
range of treatment options to alleviate symptoms.[3] 

About Rosacea: Beyond the Visible

Rosacea: Beyond the Visible is a global disease awareness campaign, launched in 
June 2018 by Galderma. The campaign was initially launched to raise awareness 
of an expert-authored report highlighting the results of a global market 
research study involving >700 people with rosacea and >550 physicians, which 
investigated the true burden of rosacea. The campaign has a dedicated Twitter 
@Beyond_visible and @Rosacea_beyondthevisible Instagram channel, through which 
information is shared and those living with rosacea and HCPs are encouraged to 
participate in conversations about the reality of life with this skin disease. 

About Beyond the visible: rosacea and psoriasis of the face

A global market research study involving 300 rosacea patients, 318 patients 
with psoriasis on the face and 361 doctors in 6 different countries (Canada, 
France, Germany, Italy, Poland and the USA) investigating their experience of 
living with, or treating patients living with, rosacea or psoriasis of the 
face. An expert-authored report of the findings was released in May 2020 and 
seeks to address three key questions – What is the true extent of the burden 
patients face? How does it differ across the two facial skin diseases? By 
looking at the impact of facial skin disease from different angles, what 
insights can we gain to help patients and doctors achieve the best outcomes? 

About Galderma

Galderma, the world's largest independent global dermatology company, was 
created in 1981 and is now present in over 100 countries with an extensive 
product portfolio of prescription medicines, aesthetics solutions and consumer 
care products.  The company partners with health care practitioners around the 
world to meet the skin health needs of people throughout their lifetime.  
Galderma is a leader in research and development of scientifically-defined and 
medically-proven solutions for the skin. For more information, please visit 

Click here to view the survey results infographic:

Galderma media relations contact: 
Sébastien Cros 
Head of Corporate Communications 

SOURCE: Galderma